AI Biomed PredictionsCRDF – ASCO Data Could Decide Cardiff Oncology’s Next Sharp Repricing ScanScor Admin / May 28, 2026
AI Biomed PredictionsACHV – ACHV Faces Make-or-Break FDA Catalyst With Sharp Upside Potential ScanScor Admin / May 24, 2026
AI Biomed PredictionsAVIR – Phase 3 HCV data could decide Atea’s next rerating ScanScor Admin / May 20, 2026
AI Biomed PredictionsLXEO – Lexeo Nears Pivotal FDA Decision That Could Reprice Shares ScanScor Admin / May 20, 2026
AI Biomed PredictionsBNTC – Benitec’s next rerating likely hinges on FDA path clarity ScanScor Admin / May 20, 2026
AI Biomed PredictionsNGNE – Mid-2026 Rett data could reignite Neurogene’s breakout case ScanScor Admin / May 12, 2026
AI Biomed PredictionsNGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through ScanScor Admin / May 10, 2026
AI Biomed PredictionsLRMR – June BLA filing could reset Larimar’s risk-reward profile ScanScor Admin / May 10, 2026
AI Biomed PredictionsAUTL – Autolus Faces Its First True Commercial Rerating Test ScanScor Admin / May 10, 2026
AI Biomed PredictionsABEO – ZEVASKYN launch proof could ignite Abeona’s next sharp rerating ScanScor Admin / May 10, 2026
